Healthcare & Medical Devices Global On demand · 24-48h

Global Human Free Prostate Specific Antigen (f-PSA) ELISA Kit Market Strategic Research Report

Global Human Free Prostate Specific Antigen (f-PSA) ELISA Ki…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Human Free Prostate Specific Antigen (f-PSA) ELISA Kit Market
$2422025
4.8%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Time-resolved Fluorescence (TRF), Magnetic-Particle-Based Chemiluminescent Immunoassay, Latex-enhanced Immunoturbidimetry (LETIA)

By Application: Clinical Diagnosis, Research Institutes, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Boster Bio, Aviva Systems Biology, FineTest, DRG International, Inc., Phoenix Pharmaceuticals, Inc., Guangzhou Darui Biotechnology Co., Ltd, Shenzhen New Industries Biomedical Engineering Co., Ltd, Beijing BGI-GBI Biotech Co., Ltd., Beijing Tongsheng Times Bio-Technology Co., Ltd., Novatein Biosciences, BioVendor, Creative Diagnostics, Crystal Chem, BioVision, Anogen-Yes Biotech Laboratories Ltd., Tianjin Boasis Biotechnology Co., Ltd., Nanjing Realmind Biotech Co., Ltd., AUTOBIO, Shandong Kanghua Biomedical Technology Co., Ltd., Beijing North Biotechnology Research Institute Co., Ltd., Beijing Unidiag Technology Co., Ltd.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 162 pages
Market size 2025
$242
Million USD
Forecast CAGR
4.8%
2025-2032
Forecast 2032
$336
Projected
Gebieden
5
Asia Pacific · Latin America · MEA · Europe · North America

Overzicht

Scope of the Report

The global Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market size is predicted to grow from US$ 242 million in 2025 to US$ 333 million in 2032; it is expected to grow at a CAGR of 4.8% from 2026 to 2032.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market?

What factors are driving Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market opportunities vary by end market size?

How does Human Free Prostate Specific Antigen (f-PSA) ELISA Kit break out by Type, by Application?

This report presents a comprehensive overview of the global Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Time-resolved Fluorescence (TRF)
  • Magnetic-Particle-Based Chemiluminescent Immunoassay
  • Latex-enhanced Immunoturbidimetry (LETIA)

Segment by Application

  • Clinical Diagnosis
  • Research Institutes
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Clinical Diagnosis, Research Institutes, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Human Free Prostate Specific Antigen (f-PSA) ELISA Kit Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 4.8%
Regional growth momentum
Market share by segment
Key metrics
Base value
$242
2025
Forecast
$336
2032
CAGR
4.8%
2025–2032
Gebieden
5
global
Key companies
Boster BioAviva Systems BiologyFineTestDRG International, Inc.Phoenix Pharmaceuticals, Inc.Guangzhou Darui Biotechnology Co., LtdShenzhen New Industries Biomedical Engineering Co., LtdBeijing BGI-GBI Biotech Co., Ltd.
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Time-resolved Fluorescence (TRF)Magnetic-Particle-Based Chemiluminescent ImmunoassayLatex-enhanced Immunoturbidimetry (LETIA)
By Application
Clinical DiagnosisResearch InstitutesOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Time-resolved Fluorescence (TRF)
  • 3.1.3 Magnetic-Particle-Based Chemiluminescent Immunoassay
  • 3.1.4 Latex-enhanced Immunoturbidimetry (LETIA)
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Clinical Diagnosis
  • 4.1.3 Research Institutes
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Boster Bio
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Aviva Systems Biology
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 FineTest
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 DRG International, Inc.
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Phoenix Pharmaceuticals, Inc.
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Guangzhou Darui Biotechnology Co., Ltd
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Shenzhen New Industries Biomedical Engineering Co., Ltd
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Beijing BGI-GBI Biotech Co., Ltd.
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Beijing Tongsheng Times Bio-Technology Co., Ltd.
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Novatein Biosciences
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 BioVendor
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Creative Diagnostics
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Crystal Chem
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 BioVision
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Anogen-Yes Biotech Laboratories Ltd.
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Tianjin Boasis Biotechnology Co., Ltd.
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Nanjing Realmind Biotech Co., Ltd.
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 AUTOBIO
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Shandong Kanghua Biomedical Technology Co., Ltd.
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Beijing North Biotechnology Research Institute Co., Ltd.
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Beijing Unidiag Technology Co.,Ltd.
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market?
The global Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market is estimated at US$ 242 million in 2025 (base year) and is projected to reach US$ 333 million by 2032.
How fast is the Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market expected to grow?
The market is expected to grow at a CAGR of 4.8% from 2026 to 2032, expanding from US$ 242 million in 2025 to US$ 333 million in 2032, roughly 1.4 times its base-year value.
What does the Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market cover?
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry.
What are the main segments of the Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market by type?
By type, the market is segmented into Time-resolved Fluorescence (TRF), Magnetic-Particle-Based Chemiluminescent Immunoassay and Latex-enhanced Immunoturbidimetry (LETIA).
Which applications drive demand in the Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market?
Key applications covered include Clinical Diagnosis, Research Institutes and Others.
Who are the key players in the Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market?
Key players profiled include Boster Bio, Aviva Systems Biology, FineTest, DRG International, Phoenix Pharmaceuticals, Guangzhou Darui Biotechnology Co., Shenzhen New Industries Biomedical Engineering Co. and Beijing BGI-GBI Biotech Co., among 21 companies covered in total.
Which regions and countries are covered for Human Free Prostate Specific Antigen (f-PSA) ELISA Kit?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market?
What factors are driving Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market growth, globally and by region?
Who should buy the Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market report?
The report is intended for manufacturers and solution providers, distributors and end users in Clinical Diagnosis, Research Institutes and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Human Free Prostate Specific Antigen (f-PSA) ELISA Kit market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from US$ 3.500,00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.